Granules India Limited, a vertically integrated fast growing Indian pharmaceutical company, announced that the US Food & Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for gabapentin tablets USP, 600 mg and 800 mg. It is bioequivalent to the reference listed drug product (RLD), Neurontin tablets, 600 mg and 800 mg, of Viatris Specialty LLC. The current annual US market for gabapentin tablets is approximately $145 million, according to MAT Jan 2023, IQVIA/IMS Health. Gabapentin tablets are indicated for management of postherpetic neuralgia in adults; and as an adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and paediatric patients 3 years and older with epilepsy. Granules now has a total of 55 ANDA approvals from US FDA (53 final approvals and 2 tentative approvals). Granules India Limited has consistently achieved manufacturing success, set new standards of quality, and expanded its presence across the world. Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered in Hyderabad with best-in-class facilities and a commitment to operational excellence, quality, and customer service.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!